On July 15, 2025, Amgen was among 986 individual stocks in the Medical sector, returning 14% while the sector average returned -3.9%. Aldeyra stock returned 0.4%.
1 report, 1 independent
Updated Jul 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
On July 15, 2025, Amgen was among 986 individual stocks in the Medical sector, returning 14% while the sector average returned -3.9%. Aldeyra stock returned 0.4%.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
Medical
Plastic Surgeon
Nothing else this week.
Related events
- Amgen Inc. trades on the NASDAQ stock exchange.
- Cantor Fitzgerald and other analyst firms issued ratings on Amgen stock, which is listed on the Nasdaq exchange.
- The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
- Joint drug trial success boosts Amgen stock.
- Reports on the top holdings of various healthcare and biotech ETFs, listing major pharmaceutical companies like Eli Lilly, Amgen, and Johnson & Johnson.
Coverage
Newest first; wire copies grouped- ZacksAre Medical Stocks Lagging Amgen (AMGN) This Year? The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amgen (AMG